|
|
Article: New Torcetrapib/Atorvastatin Research Further Supports Raising 'Good' HDL Cholesterol.
- Article from:
- PR Newswire
- Article date:
- March 14, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Torcetrapib/Atorvastatin Clinical Trial Program is the Largest Ever Conducted by Pfizer: 25,000 Patients Enrolled in Studies Underway Around the World * Pfizer Clinician: "First Data to Show that there are Important Differences in Raising HDL Cholesterol Levels with Torcetrapib and Atorvastatin Depending on Whether it is Dosed in the Morning or Evening" * TNT Trial Investigator: "The TNT Sub-Analysis Suggests that HDL Cholesterol May Also Provide Important Therapeutic Benefits that May Result in Further Reductions in Cardiovascular Risk"
ATLANTA, March 14 /PRNewswire-FirstCall/ -- Pfizer said today that new data, involving its medicine in development ...